Nutriband (NASDAQ:NTRB) Releases Earnings Results

Nutriband (NASDAQ:NTRB) announced its earnings results on Thursday. The company reported ($0.10) EPS for the quarter, Zacks reports. Nutriband had a negative net margin of 403.98% and a negative return on equity of 118.33%.

Nutriband Stock Performance

NTRB traded up $0.11 during trading on Thursday, hitting $3.52. The stock had a trading volume of 4,961 shares, compared to its average volume of 12,155. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.21 and a current ratio of 6.36. The firm has a market capitalization of $42.79 million, a P/E ratio of -1.35 and a beta of 1.90. The company’s 50-day moving average price is $3.75 and its 200 day moving average price is $4.19. Nutriband has a twelve month low of $3.21 and a twelve month high of $11.68.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.

Institutional Investors Weigh In On Nutriband

A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. lifted its stake in shares of Nutriband Inc. (NASDAQ:NTRB) by 1.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 202,738 shares of the company’s stock after acquiring an additional 3,111 shares during the period. Vanguard Group Inc. owned 1.68% of Nutriband worth $1,429,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 19.70% of the company’s stock.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.